Adelphia Recovery Trust Veh CVV Series ACC-1 Int (ADPAS)
Adelphia Recovery Trust Veh CVV Series ACC-1 Int (ADPAS) Financials Nov 11, 2014, 8:10 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Adelphia Recovery Trust Veh CVV Series ACC-1 Int
Fiscal year is January-December. All values USD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 40M 174.98M 0 0 0
Cost of Goods Sold (COGS) incl. D&A 0 0 0 - -
COGS excluding D&A 0 0 0 - -
Depreciation & Amortization Expense 0 0 0 0 0
Depreciation 0 0 0 0 0
Amortization of Intangibles 0 0 0 0 0
Gross Income 40M 174.98M 0 - -
2009 2010 2011 2012 2013 5-year trend
SG&A Expense 2.09M 2.09M 3M 2.37M 2.07M
Research & Development 0 0 0 0 0
Other SG&A 2.09M 2.09M 3M 2.37M 2.07M
Other Operating Expense 37.58M 34.87M 8.49M 0 0
Unusual Expense 0 0 0 (27.43M) -
EBIT after Unusual Expense 0 0 0 27.43M -
Non Operating Income/Expense 0 0 0 0 0
Non-Operating Interest Income 807,190 622,868 490,250 418,947 420,832
Equity in Affiliates (Pretax) 0 0 0 - 0
Interest Expense 0 0 0 0 -
Gross Interest Expense 0 0 0 0 -
Interest Capitalized 0 0 0 0 -
Pretax Income 1.14M 138.64M (10.99M) 25.48M (1.65M)
Income Tax 0 0 0 0 0
Income Tax - Current Domestic 0 0 0 - -
Income Tax - Current Foreign 0 0 0 - -
Income Tax - Deferred Domestic 0 0 0 - -
Income Tax - Deferred Foreign 0 0 0 - -
Income Tax Credits 0 0 0 - -
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income 1.14M 138.64M (10.99M) 25.48M (1.65M)
Minority Interest Expense 0 0 0 0 0
Net Income 1.14M 138.64M (10.99M) 25.48M (1.65M)
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 - 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries 1.14M 138.64M (10.99M) 25.48M (1.65M)
Preferred Dividends 0 0 0 0 0
Net Income Available to Common 1.14M 138.64M (10.99M) 25.48M (1.65M)
EPS (Basic) - - - - -
Basic Shares Outstanding - - - - -
EPS (Diluted) - - - - -
Diluted Shares Outstanding - - - - -
EBITDA 329,585 138.02M (11.48M) (2.37M) (2.07M)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Trouble Is Brewing for Hims & Hers Investors This isn't your typical quiet stroll through the park when it comes to Hims & Hers Health, Inc. (NYSE: HIMS). We're talking about a full-blown legal showdown that's unfolding faster than you can say 'telehealth scandal.' October 25, 2026, saw the kind of announcement that makes seasoned investors' hearts skip a beat if they've...
Continue Reading
Are Slim iPhone Cases Really Protecting Your Investment? Anyone who's dropped a brand-new phone knows the pain of watching your investment smack the concrete. But hey, welcome to 2026, where Consumer365's latest rundown on iPhone protective gear turns the spotlight on TORRAS. These folks grabbed attention with their Q3 Air and Q3 Air Pro cases, crafted for iPhone 18 Pro...
Continue Reading
Everyone wants a cozy, energy-efficient home, right? Well, the first step to achieving that might just surprise you. Forget about shoving more insulation into the walls for a second; air sealing should be your starting line. That's the drum Insulation Expert Mike Mancuso is beating, and he's got a point worth considering before you touch another insulation panel. Cracking...
Continue Reading
Satellite Services Take Off in the Middle East Never thought the day would come where the Middle East is on the threshold of leapfrogging satellite tech, but here we are. ST Engineering iDirect just locked arms with MBSat—yep, that's part of the Mohammed Al Barwani Group—to birth a next-gen satellite connectivity service hub in Oman and across surrounding areas....
Continue Reading
A Star-Studded Start to the Season of Giving Miranda Lambert is set to dazzle audiences yet again, and if there's one thing this country music titan knows, it's how to crank up the heartstrings while fanning the flames of generosity. She'll take to the stage at AT&T Stadium this Thanksgiving during the Dallas Cowboys game, bringing a powerful performance to light up the...
Continue Reading
Investor Alert: Gildan's Legal Showdown Alright, here's a twist you didn't see coming—or maybe you did if you've been tracking the ticker tapes like a hawk. Gildan Activewear Inc. (NYSE:GIL) is stuck in the kind of hot water that can scald the bottom line. The Stakes: Racing Towards December 14 Marked on your calendar, December 14, is a date of some significance if...
Continue Reading
Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...
Continue Reading
Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...
Continue Reading
Where Energy Drinks and Digital Reality Collide Monster Energy sure knows how to throw a party, especially when it hinges on something as electrifying as Call of Duty: Modern Warfare 4. Imagine this: Cosm Los Angeles is decked out with a massive 87-foot LED dome, and every gamer, celeb, and influencer ready to dive right in. You can't make this stuff up. They've mashed...
Continue Reading
Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...
Continue Reading
Top 5 Most Recently Viewed Articles
Warner Bros. Discovery Experiences Impressive Stock Surge Warner Bros. Discovery Inc. (NASDAQ: WBD) has been making headlines recently, with its stock surging dramatically. Investors and market enthusiasts are keenly observing this upward trend, particularly following a substantial rally. Record-Breaking Rally The company achieved an incredible milestone with its largest...
Continue Reading
Stellantis Faces Significant Q3 Shipment Decline Stellantis (EPA: STLAM) (NYSE: STLA) recently reported a 20% drop in global shipments for the third quarter, prompting a notable reaction in the markets. The decline has been attributed to several factors including strategic inventory reduction measures and delays in the release of new models. During this challenging...
Continue Reading
Stifel Stands Firm on Elanco Animal Health Stifel, a prominent financial services firm, has recently reaffirmed its Buy rating for Elanco Animal Health (NYSE: ELAN) and has kept its price target at $20.00 per share. This decision comes on the heels of the U.S. Food and Drug Administration's (FDA) approval of Elanco's new drug, Zenrelia, which serves as a significant boost...
Continue Reading
ChargePoint and Siemens Lead the Charge in Clean Tech The clean tech revolution is moving at an impressive pace, particularly with the growth of electric vertical takeoff and landing (eVTOL) aircraft and electric vehicle (EV) infrastructure. Companies like ChargePoint Holdings Inc (NYSE: CHPT) and Siemens AG (OTCPK: SIEGY) are crucial in shaping a sustainable future for...
Continue Reading
Opportunities for Investors in Elevance Health Class Action The recent developments surrounding Elevance Health, Inc. have prompted considerable attention, particularly among investors who have experienced substantial financial losses. The law firm Robbins Geller Rudman & Dowd LLP has initiated a class action lawsuit targeting Elevance Health, which operates in the health...
Continue Reading